Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin +/- Envafolimab in CDK12-mutated mCRPC
NCT06663007Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Sep 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The Second Hospital of Tianjin Medical University. Started Sep 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06663007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663007.